行情

SGMO

SGMO

SANGAMO THERAPEU
NASDAQ

实时行情|Nasdaq Last Sale

6.34
-0.32
-4.80%
已收盘, 18:37 03/27 EDT
开盘
6.50
昨收
6.66
最高
6.58
最低
6.28
成交量
168.67万
成交额
--
52周最高
13.91
52周最低
4.810
市值
7.36亿
市盈率(TTM)
-7.2573
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测SGMO价格均价为20.67,最高价位36.00,最低价为10.00。

EPS

SGMO 新闻

更多
  • 3 Top Stocks You've Probably Never Heard Of
  • MotleyFool.com · 1天前
  • Stocks To Watch: Investors Stay The Distance
  • Seeking Alpha - Article · 1天前
  • Sangamo Therapeutics: Market Cap Is At A Bargain Relative To Its Cash Position
  • Seeking Alpha - Article · 4天前
  • Are These Warren Buffett Stocks a Buy at Beaten-Down Prices?
  • MotleyFool.com · 6天前

所属板块

生物技术和医学研究
-2.44%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

SGMO 简况

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.
展开

微牛提供Sangamo Therapeutics Inc(NASDAQ-SGMO)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的SGMO股票新闻,以帮助您做出投资决策。